Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Largest Sleep Apnea Trial Backs CPAP For Improving QoL, Not For Lowering Secondary Cardio Events

Executive Summary

In the largest sleep apnea study ever conducted, continuous positive airway pressure (CPAP) did not appear to lower the risk of cardiovascular adverse events including cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina in patients with obstructive sleep apnea and known cardiovascular disease. However, patients in the trial only used CPAP a few hours a night, on average, indicating that an easier-to-use version of CPAP might yield better outcomes.

You may also be interested in...



Respicardia's remedē Neurostimulator Improves Sleep Apnea Symptoms In Pivotal Trial

The implantable neurostimulation system works automatically and continuously during every hour of sleep and does not depend on patient adherence, which has been a major limitation of continuous positive airway pressure therapy.

Obstructive Sleep Apnea: CPAP Under Pressure As New Market Segments Awaken

An estimated 15 million Americans have obstructive sleep apnea severe enough to warrant treatment, but this field has been chronically underserved by traditional continuous positive airway pressure systems that are inconvenient and uncomfortable to use. To address this problem, CPAP manufacturers are making design improvements to optimize comfort and compliance; at the same time, promising new technologies are emerging – including neurostimulation devices for OSA – that could help reshape the future management of this often overlooked, but serious disorder.

TCT 2022: Trial Of Boston Scientific’s TAVR Embolic Protector Misses Endpoint, But May Offer 'Hope'

New trial data shows Boston Scientific’s Sentinel cerebral embolic protection device may reduce the risk of disabling stroke, but it does not appear to reduce the overall risk of stroke.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT103769

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel